Beyond Chemotherapy: The Promise of Immunotherapy in Cancer Care and Advancements in Cancer Therapy

Zaid Khan

doi:10.37591/rrjoi.v13i2.3323

Abstract

Recent advances in cancer immunotherapy harness the immune system to precisely target cancer. These include the use of immunosuppressive agents, NK cell recovery, changes in tumor microenvironment metabolic, and aging to achieve a positive tumor response The article explores how the body development of the immune system in the late 19th century, highlighting milestones such as the discovery and FDA approval of IL2. Different categories of immunology are explored, from monoclonal antibodies to CAR-T cell therapies, with emphasis on potential and challenges. It emphasizes the role of the immune system in cancer prevention and includes drugs that block the immune system, such as PD-1/PD-L1 and CTLA-4 blockers , their approaches, clinical success, and combination therapies are discussed The promising field of CAR-T cell therapy is broad, including technology, product development, challenges, future prospects and availability. In addition, oncolytic viruses such as T-VEC and HSV-1-based therapy show promise in cancer treatment. Ongoing research has been published on the treatment of oncolytic viruses for a variety of cancers, including triple negative breast cancer. Although challenges such as resistance to therapy remain, future developments include neoantigen vaccines, personalized medicine and nanomedicines to enhance drug delivery and reduce side effects Immunotherapy dramatically extends patients' lives and improves their quality of life, offering hope for advanced cancer treatment.

Abstract

Keywords